Vaxart Newsroom

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

newsfilter.ioAug 30 20:00

Vaxart's Pre-clinical Data Reveals Potential Of Mucosal Vaccine Platform For HPV- Cervical Dysplasia

RTTNewsAug 28 22:09

Vaxart Dips on Test Results

Baystreet.caAug 28 21:52

Express News | Vaxart- Co's Hpv Vaccine Constructs Can Stimulate Potent Immune Response Against Hpv16 Proteins E6 & E7

BreakingsAug 28 20:04

Express News | Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for Hpv-Related Cervical Dysplasia

BreakingsAug 28 20:00

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of Its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia

VaxartAug 28 12:00

Vaxart, Inc.'s (NASDAQ:VXRT) 39% Share Price Surge Not Quite Adding Up

Simply Wall StAug 20 18:07

B.Riley Financial Maintains Vaxart(VXRT.US) With Buy Rating, Maintains Target Price $2.5

B.Riley Financial analyst Mayank Mamtani maintains $Vaxart(VXRT.US)$ with a buy rating, and maintains the target price at $2.5.According to TipRanks data, the analyst has a success rate of 26.4% and

Futu NewsAug 16 20:31 · Ratings

Vaxart's Promising Vaccine Pipeline: Leading in Mucosal Immunity With Government Support and Competitive Advantages

TipRanksAug 16 19:45

Oral vaccines have broad prospects. O'Brien, Homer, gives Vaxart (vaxart.US) an 'outperform' rating against the large cap market.

Initiating coverage on Vaxart (VXRT.US) with an outperform rating and target price of $4, which is expected to outperform the overall market.

Zhitong FinanceAug 16 11:47 · Ratings

Oppenheimer Starts Vaxart at Outperform, Cites Oral Vaccine Focus

Seeking AlphaAug 16 03:53

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside

BenzingaAug 16 01:57

Oppenheimer Initiates Vaxart at Outperform With $4 Price Target

MT NewswiresAug 15 19:24 · Ratings

Vaxart Analyst Ratings

BenzingaAug 15 17:26 · Ratings

Express News | Vaxart Inc : Oppenheimer Initiates Coverage With Outperform Rating and $4 Target Price

BreakingsAug 15 12:31

Vaxart Second Quarter 2024 Earnings: Misses Expectations

Yahoo FinanceAug 11 21:19

Earnings Call Summary | Vaxart(VXRT.US) Q2 2024 Earnings Conference

Futu NewsAug 9 11:27 · Conference Call

Vaxart | 10-Q: Q2 2024 Earnings Report

SECAug 9 04:24 · Announcements

Vaxart 2Q Loss/Shr 9c >VXRT

Dow JonesAug 9 04:02

Vaxart 2Q Rev $6.4M >VXRT

Dow JonesAug 9 04:02